{"id":952894,"date":"2026-04-20T09:05:36","date_gmt":"2026-04-20T13:05:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/"},"modified":"2026-04-20T09:05:36","modified_gmt":"2026-04-20T13:05:36","slug":"gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/","title":{"rendered":"GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm\u00a0"},"content":{"rendered":"<div class=\"mw_release\">\n<p>PHILADELPHIA, April  20, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xQ9s-Yor0wI7t8bsERoKbYqXG3tX12fjSLoPEKgWGz470cE91UaM5efaGdR-nN4T1SnBTETr0lJPXmHXYuc5l5cr1_D6vAUrirgLVHMjR3k=\" rel=\"nofollow\" target=\"_blank\">Kaskela Law LLC<\/a> announces that it is investigating Gyre Therapeutics, Inc.\u00a0(NASDAQ: GYRE) (\u201cGyre\u201d) on behalf of the company\u2019s investors.\u202f\u202f\u00a0<\/p>\n<p>The investigation seeks to determine whether Gyre and\/or the company\u2019s officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.\u202f\u202f\u00a0<\/p>\n<p>\n        <strong><br \/>\n          <em>Gyre shareholders who would like to learn more about the investigation and their legal rights and options are encouraged to contact lead investigative attorney Adrienne Bell, Esq. at (484) 229 \u2013 0750, by email at <\/em><br \/>\n        <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Cg0WPHsBXwSwiioeEIPS10AWZmVqoDVMKivooTt_DzjUdZEXRWc5DWvw0xgz_Unut2M6PHJ5kwxSFF4sFQMgAYxPVDRlyA-a029gUwHjZN4=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em>abell@kaskelalaw.com<\/em><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong><br \/>\n          <em>, or by filling out our online form at:<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3ZCWYa6RRHxAMlwB9VSLgMk_6n0POgcm6yszE0DjmkYEflwqIS_rLS4kslm6Gq-xxO9wtWSq7Be0pME9rPqS74EZWxlpxKKCf_frvPlaqkGb9Xh99dVdIBlk-zJRkWvGZylESzHg5sVa3AToeUDYljpDoHMCwiFmlNw5ZriQqBQ=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em>https:\/\/kaskelalaw.com\/case\/gyre-therapeutics\/<\/em><br \/>\n          <\/strong><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <strong><br \/>\n          <u>ABOUT KASKELA LAW:<\/u><br \/>\n        <\/strong>\u00a0\u00a0\u00a0<\/p>\n<p>Kaskela Law <em>exclusively <\/em>represents investors in securities\u00a0fraud, corporate governance, and merger &amp; acquisition litigation on a contingent basis. For additional information about the firm, including our recent monetary recoveries for investors, please visit our website (www.kaskelalaw.com) or contact us today at (888) 715 \u2013 1740.<\/p>\n<p>\n        <strong>KASKELA LAW LLC<\/strong>\u00a0 <br \/>D.\u00a0Seamus Kaskela, Esquire <br \/>Adrienne Bell, Esquire <br \/>18 Campus Boulevard, Suite 100 <br \/>Newtown Square, PA\u00a019073 <br \/>(484) 229 \u2013 0750 \u00a0 <br \/>www.kaskelalaw.com<\/p>\n<p>This communication may constitute attorney advertising in certain jurisdictions.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MjM4OCM3NTQyNjM1IzIwOTk5MzU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjU3NTY1YjItNzNiZi00M2RkLTk4MTUtNDA1YzZjYzg2MTBhLTExMTE1MDYtMjAyNi0wNC0yMC1lbg==\/tiny\/Kaskela-Law.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA, April 20, 2026 (GLOBE NEWSWIRE) &#8212; Kaskela Law LLC announces that it is investigating Gyre Therapeutics, Inc.\u00a0(NASDAQ: GYRE) (\u201cGyre\u201d) on behalf of the company\u2019s investors.\u202f\u202f\u00a0 The investigation seeks to determine whether Gyre and\/or the company\u2019s officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.\u202f\u202f\u00a0 Gyre shareholders who would like to learn more about the investigation and their legal rights and options are encouraged to contact lead investigative attorney Adrienne Bell, Esq. at (484) 229 \u2013 0750, by email at abell@kaskelalaw.com , or by filling out our online form at: https:\/\/kaskelalaw.com\/case\/gyre-therapeutics\/ ABOUT KASKELA LAW: \u00a0\u00a0\u00a0 Kaskela Law exclusively represents investors in securities\u00a0fraud, corporate governance, and merger &amp; acquisition litigation on a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm\u00a0&#8220;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-952894","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm\u00a0 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm\u00a0 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, April 20, 2026 (GLOBE NEWSWIRE) &#8212; Kaskela Law LLC announces that it is investigating Gyre Therapeutics, Inc.\u00a0(NASDAQ: GYRE) (\u201cGyre\u201d) on behalf of the company\u2019s investors.\u202f\u202f\u00a0 The investigation seeks to determine whether Gyre and\/or the company\u2019s officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.\u202f\u202f\u00a0 Gyre shareholders who would like to learn more about the investigation and their legal rights and options are encouraged to contact lead investigative attorney Adrienne Bell, Esq. at (484) 229 \u2013 0750, by email at abell@kaskelalaw.com , or by filling out our online form at: https:\/\/kaskelalaw.com\/case\/gyre-therapeutics\/ ABOUT KASKELA LAW: \u00a0\u00a0\u00a0 Kaskela Law exclusively represents investors in securities\u00a0fraud, corporate governance, and merger &amp; acquisition litigation on a &hellip; Continue reading &quot;GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm\u00a0&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-20T13:05:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MjM4OCM3NTQyNjM1IzIwOTk5MzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm\u00a0\",\"datePublished\":\"2026-04-20T13:05:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\\\/\"},\"wordCount\":196,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MjM4OCM3NTQyNjM1IzIwOTk5MzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\\\/\",\"name\":\"GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm\u00a0 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MjM4OCM3NTQyNjM1IzIwOTk5MzU=\",\"datePublished\":\"2026-04-20T13:05:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MjM4OCM3NTQyNjM1IzIwOTk5MzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MjM4OCM3NTQyNjM1IzIwOTk5MzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm\u00a0 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/","og_locale":"en_US","og_type":"article","og_title":"GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm\u00a0 - Market Newsdesk","og_description":"PHILADELPHIA, April 20, 2026 (GLOBE NEWSWIRE) &#8212; Kaskela Law LLC announces that it is investigating Gyre Therapeutics, Inc.\u00a0(NASDAQ: GYRE) (\u201cGyre\u201d) on behalf of the company\u2019s investors.\u202f\u202f\u00a0 The investigation seeks to determine whether Gyre and\/or the company\u2019s officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.\u202f\u202f\u00a0 Gyre shareholders who would like to learn more about the investigation and their legal rights and options are encouraged to contact lead investigative attorney Adrienne Bell, Esq. at (484) 229 \u2013 0750, by email at abell@kaskelalaw.com , or by filling out our online form at: https:\/\/kaskelalaw.com\/case\/gyre-therapeutics\/ ABOUT KASKELA LAW: \u00a0\u00a0\u00a0 Kaskela Law exclusively represents investors in securities\u00a0fraud, corporate governance, and merger &amp; acquisition litigation on a &hellip; Continue reading \"GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm\u00a0\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-20T13:05:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MjM4OCM3NTQyNjM1IzIwOTk5MzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm\u00a0","datePublished":"2026-04-20T13:05:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/"},"wordCount":196,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MjM4OCM3NTQyNjM1IzIwOTk5MzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/","name":"GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm\u00a0 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MjM4OCM3NTQyNjM1IzIwOTk5MzU=","datePublished":"2026-04-20T13:05:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MjM4OCM3NTQyNjM1IzIwOTk5MzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MjM4OCM3NTQyNjM1IzIwOTk5MzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gyre-therapeutics-kaskela-law-announces-investigation-of-gyre-therapeutics-inc-gyre-and-encourages-shareholders-to-contact-the-firm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=952894"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952894\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=952894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=952894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=952894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}